Skip to main content
. 2022 Sep 12;13:5362. doi: 10.1038/s41467-022-33036-y

Fig. 1. Screening, randomization, and follow-up of patients.

Fig. 1

Patients randomized to an additional mRNA vaccine dose received the same compound as with their primary vaccination. Patients were blinded to the type of vaccine used until week 4.